CooperCompanies completed the acquisition of Generate Life Sciences from GI Partners for $1.6bn.

CooperCompanies, a global medical device company, completed the acquisition of Generate Life Sciences, a life sciences platform that provides reproductive and newborn stem cell services, from GI Partners, a private investment firm, for $1.6bn. "This acquisition is a strong strategic fit for CooperSurgical as it allows us to better serve fertility clinics and Ob/Gyns with a more extensive suite of products and services. As a leader in women’s healthcare, this is an important addition to our existing offerings and allows us to leverage our infrastructure and expertise, including our sales forces’ strong clinical reputation and educational capabilities," Al White, Cooper President and CEO.